Supplement to:
Phase-3 Dose Selection of Marzeptacog Alfa (Activated) Informed by Population Pharmacokinetic Modeling: A Novel Hemostatic Drug

Alan Faraj¹, Tom Knudsen², Shraddha Desai², Linda Neuman², Grant E. Blouse², Ulrika S.H. Simonsson**

Affiliations:
¹Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
²Catalyst Biosciences, South San Francisco, CA, USA
Figure S2. Visual predictive checks of the final population PK model on log scale for different dose levels following SC dosing. The solid and dashed lines are the median and, 2.5\textsuperscript{th} and 97.5\textsuperscript{th} percentiles of the observed data, respectively. The shaded areas (top to bottom) are the 95\% confidence intervals of the 97.5\textsuperscript{th} (light grey), median (dark grey) and 2.5\textsuperscript{th} (light grey) percentiles of the simulated data. Open circles are observation points. The 30 μg/kg dose group had two observations at later time points but the VPC is cut for readability.